Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy

Background: VPM1002BC is a modified mycobacterium Bacillus Calmette Guérin (BCG) for the treatment of non-muscle invasive bladder cancer (NMIBC). The genetic modifications are expected to result in better immunogenicity and less side effects. We report on patient safety and immunology of the first i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Rentsch, Cyrill A., Bosshard, Piet, Mayor, Grégoire, Rieken, Malte, Püschel, Heike, Wirth, Grégory, Cathomas, Richard, Parzmair, Gerald P., Grode, Leander, Eisele, Bernd, Sharma, Hitt, Gupta, Manish, Gairola, Sunil, Shaligram, Umesh, Goldenberger, Daniel, Spertini, François, Audran, Régine, Enoiu, Milica, Berardi, Simona, Hayoz, Stefanie, Wicki, Andreas
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2020
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7185202/
https://ncbi.nlm.nih.gov/pubmed/32363120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1748981
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados